Dare Bioscience
Update in progressDARE (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Daré Bioscience, Inc. develops therapies for contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. Its portfolio includes XACIATO for bacterial vaginosis; Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream for female arousal; and DARE-HRT1 for menopausal vasomotor symptoms. It also pursues DARE-VVA1, DARE-HPV, and additional vaginal health and fertility programs.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.26
- Governance
- 0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMs. Sabrina Martucci Johnson
- Founded2015
- Employees21
- Websitedarebioscience.com
Identifiers
- ISINUS23666P2002
- FIGIBBG001J2P362
- CUSIP15708Q105
- CIK0001401914